Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Antoine Lacassagne
With
Centre Méditerranéen de Médecine Moléculaire UMR_S-1065
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patient with metastatic prostate cancer
Patient having a biopsy programmed as part of his care.
Patient having a biopsy programmed as part of hiscare.
Patient with sufficient tumor volume after imaging data review by the radiologist to guarantee a sufficient quantity of material for the diagnosis of biopsy and additional material for the study.
INR \<1.5; Platelets \> 50000 / μL
You may not be if
Patient under age of 18 years.
Patient under Plavix or Effient or Ticlid without possibility of suspension for 5 days, low molecular weight heparin without possibility of suspension of the dose before the intervention, or Fondaparinux without possibility of suspension, or ReoPro without possibility of suspension for 24h and aPTT \<50s and ACT \<150s, or Integrilin or Aggrastat or Argatroban without possibility of suspension 4 H before the intervention, or Angiomax without possibility of suspending 2H to 3H if CrCL\> 50 mL / min or 3H to 5h if CrCL \<50 mL / min before the intervention or and Pradaxa without possibility of suspension 2 to 3 days if CrCL\> 50 mL / min or 3 to 5 days if CrCL \<50 mL / min before the procedure
Patient under desmopressin acetate (DDAVP)
Patient with HIV or Hepatitis C positive or Hepatitis B infection, defined by either a detection of the HBs antigen or the presence of anti HBc antibodies without HBs antibody detectable.
